Ocular toxicity from systemically administered xenobiotics

Bibliography

• Brick DC. Medication errors result in costly claims for ophthalmologists. Surv Ophthalmol 1995;40(3):232-6
   PubMed Web of Science ®Google Scholar
• Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: recognition and management. Drugs 2007;67(1):75-93
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Valluri S. Ocular toxicity associated with systemic drug therapy. Curr Opin Ophthalmol 1999;10(6):438-46
   PubMedGoogle Scholar
• Blomquist PH. Ocular complications of systemic medications. Am J Med Sci 2011;342(1):62-9
   PubMedGoogle Scholar
• Garralda Luquin A. Ocular toxicity induced by medication. An Sist Sanit Navar 2008;31(Suppl 3):147-53
   PubMedGoogle Scholar
• Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol 2004;15(6):541-8
   PubMedGoogle Scholar
• Sodi A, Ioannidis A, Pitz S. Ophthalmological manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 26
   Google Scholar
• Francois J. Cornea verticillata. Bull Soc Belge Ophtalmol 1968;150:656-70
   PubMedGoogle Scholar
• Dua HS, Singh A, Gomes JA, Vortex or whorl formation of cultured human corneal epithelial cells induced by magnetic fields. Eye (Lond) 1996;10(Pt 4):447-50
   PubMedGoogle Scholar
• D'Amico DJ, Kenyon KR. Drug-induced lipidoses of the cornea and conjunctiva. Int Ophthalmol 1981;4(1-2):67-76
   PubMedGoogle Scholar
• Ahn J, Wee WR, Lee JH, Hyon JY. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean J Ophthalmol 2011;25(5):355-7
   PubMedGoogle Scholar
• Zhang G, Basti S, Jampol LM. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea 2007;26(7):858-60
   PubMedGoogle Scholar
• Tullo AB, Esmaeli B, Murray PI, Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Phase I and II clinical trials. Eye (Lond) 2005;19(7):729-38
   PubMedGoogle Scholar
• Yano S, Kondo K, Yamaguchi M, Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003;23(5A):3639-50
   PubMed Web of Science ®Google Scholar
• Yeh S, Fine HA, Smith JA. Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea 2009;28(6):699-702
   PubMedGoogle Scholar
• Salomao SR, Watanabe SE, Berezovsky A, Motono M. Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use. Curr Eye Res 2007;32(4):345-52
   PubMed Web of Science ®Google Scholar
• Noureddin BN, Seoud M, Bashshur Z, Ocular toxicity in low-dose tamoxifen: a prospective study. Eye (Lond) 1999;13(Pt 6):729-33
   PubMedGoogle Scholar
• Pavlidis NA, Petris C, Briassoulis E, Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992;69(12):2961-4
   PubMed Web of Science ®Google Scholar
• Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol 1982;66(10):676-9
   PubMed Web of Science ®Google Scholar
• Dolan BJ, Flach AJ, Peterson JS. Amiodarone keratopathy and lens opacities. J Am Optom Assoc 1985;56(6):468-70
   PubMedGoogle Scholar
• Harris L, McKenna WJ, Rowland E, Krikler DM. Side effects and possible contraindications of amiodarone use. Am Heart J 1983;106(4 Pt 2):916-23
   PubMed Web of Science ®Google Scholar
• Erdurmus M, Selcoki Y, Yagci R, Hepsen IF. Amiodarone-induced keratopathy: full-thickness corneal involvement. Eye Contact Lens 2008;34(2):131-2
   PubMedGoogle Scholar
• Haug SJ, Friedman AH. Identification of amiodarone in corneal deposits. Am J Ophthalmol 1991;111(4):518-20
   PubMed Web of Science ®Google Scholar
• D'Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol 1981;99(2):257-61
   PubMed Web of Science ®Google Scholar
• Wasielica-Poslednik J, Pfeiffer N, Reinke J, Pitz S. Confocal laser-scanning microscopy allows differentiation between Fabry disease and amiodarone-induced keratopathy. Graefes Arch Clin Exp Ophthalmol 2011;249(11):1689-96
   PubMedGoogle Scholar
• Rivera RP, Younge BR, Dyer JA. Atypical amiodarone-induced keratopathy in a patient wearing soft contact lenses. CLAO J 1989;15(3):219-21
   PubMedGoogle Scholar
• Thystrup JD, Fledelius HC. Retinal maculopathy possibly associated with amiodarone medication. Acta Ophthalmol (Copenh) 1994;72(5):639-41
   PubMed Web of Science ®Google Scholar
• Feiner LA, Younge BR, Kazmier FJ, Optic neuropathy and amiodarone therapy. Mayo Clin Proc 1987;62(8):702-17
   PubMed Web of Science ®Google Scholar
• Lochhead J, Salmon JF, Bron AJ. Cytarabine-induced corneal toxicity. Eye (Lond) 2003;17(5):677-8
   PubMedGoogle Scholar
• Fintelmann RE, Qian Y, Skalet A, Jeng BH. Anterior uveitis associated with high-dose cytosine arabinoside. Ocul Immunol Inflamm 2010;18(6):485-7
   PubMed Web of Science ®Google Scholar
• Guthoff T, Tietze B, Meinhardt B, Cytosine-arabinoside-induced keratopathy: a model of corneal proliferation kinetics. Ophthalmologica 2010;224(5):308-11
   PubMedGoogle Scholar
• Hopen G, Mondino BJ, Johnson BL, Chervenick PA. Corneal toxicity with systemic cytarabine. Am J Ophthalmol 1981;91(4):500-4
   PubMedGoogle Scholar
• Lazarus HM, Hartnett ME, Reed MD, Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol 1987;104(5):476-80
   PubMedGoogle Scholar
• Kumar L, Dua H, Agarwal S, Ocular toxicity of low dose cytosar. NZ Med J 1987;100(825):361
   PubMedGoogle Scholar
• Lass JH, Lazarus HM, Reed MD, Herzig RH. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am J Ophthalmol 1982;94(5):617-21
   PubMedGoogle Scholar
• Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs 2010;24(6):501-26
   PubMed Web of Science ®Google Scholar
• Toshida H, Uesugi Y, Ebihara N, Murakami A. In vivo observations of a case of chlorpromazine deposits in the cornea using an HRT II Rostock corneal module. Cornea 2007;26(9):1141-3
   PubMedGoogle Scholar
• Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol 2001;132(3):299-305
   PubMed Web of Science ®Google Scholar
• Fraunfelder FT, LaBraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol 1985;100(4):534-7
   PubMed Web of Science ®Google Scholar
• Rumsfield JA, West DP, Tse CS, Isotretinoin in severe, recalcitrant cystic acne: a review. Drug Intell Clin Pharm 1983;17(5):329-33
   PubMedGoogle Scholar
• Labiris G, Katsanos A, Karapetsa M, Association between isotretinoin use and central retinal vein occlusion in an adolescent with minor predisposition for thrombotic incidents: a case report. J Med Case Reports 2009;3:58
   PubMedGoogle Scholar
• Ellies P, Dighiero P, Legeais JM, Persistent corneal opacity after oral isotretinoin therapy for acne. Cornea 2000;19(2):238-9
   PubMed Web of Science ®Google Scholar
• Kaur I, Ram J, Kumar B, Effect of clofazimine on eye in multibacillary leprosy. Indian J Lepr 1990;62(1):87-90
   PubMedGoogle Scholar
• Craythorn JM, Swartz M, Creel DJ. Clofazimine-induced bull's-eye retinopathy. Retina 1986;6(1):50-2
   PubMedGoogle Scholar
• Ohman L, Wahlberg I. Letter: ocular side-effects of clofazimine. Lancet 1975;2(7941):933-4
   PubMedGoogle Scholar
• Walinder PE, Gip L, Stempa M. Corneal changes in patients treated with clofazimine. Br J Ophthalmol 1976;60(7):526-8
   PubMedGoogle Scholar
• Font RL, Sobol W, Matoba A. Polychromatic corneal and conjunctival crystals secondary to clofazimine therapy in a leper. Ophthalmology 1989;96(3):311-15
   PubMedGoogle Scholar
• Barot RK, Viswanath V, Pattiwar MS, Torsekar RG. Crystalline deposition in the cornea and conjunctiva secondary to long-term clofazimine therapy in a leprosy patient. Indian J Ophthalmol 2011;59(4):328-9
   PubMedGoogle Scholar
• Budde M, Gusek-Schneider GC, Mayer U, Seitz B. Annular crystalline keratopathy in association with immunoglobulin therapy for pyoderma gangrenosum. Cornea 2003;22(1):82-5
   PubMedGoogle Scholar
• Ormerod LD, Collin HB, Dohlman CH, Paraproteinemic crystalline keratopathy. Ophthalmology 1988;95(2):202-12
   PubMedGoogle Scholar
• Osusky R, Morell A, Imbach P, Lerch PG. Diffusion of immunoglobulins into rabbit cornea after subconjunctival injection: experimental demonstration and mathematical model. Graefes Arch Clin Exp Ophthalmol 1993;231(2):122-8
   PubMed Web of Science ®Google Scholar
• Koo H, Oh DH, Chun YS, Kim JC. A case of crystalline keratopathy in monoclonal gammopathy of undetermined significance (MGUS). Korean J Ophthalmol 2011;25(3):202-5
   PubMedGoogle Scholar
• Lisch W, Saikia P. Immunotactoid microtubular corneal deposits in bilateral paraprotein crystalline keratopathy and atypical corneal immunoglobulin deposition in a patient with dysproteinemia. Cornea 2011;30(2):247; author reply -8
   PubMedGoogle Scholar
• Matoba AY, Chevez-Barrios P, Jones DB. Atypical corneal immunoglobulin deposition in a patient with dysproteinemia. Cornea 2010;29(1):105-7
   PubMedGoogle Scholar
• Singh K. Immunotactoid microtubular corneal deposits in bilateral paraprotein crystalline keratopathy. Cornea 2009;28(7):829-31
   PubMedGoogle Scholar
• McCormick SA, DiBartolomeo AG, Raju VK, Schwab IR. Ocular chrysiasis. Ophthalmology 1985;92(10):1432-5
   PubMed Web of Science ®Google Scholar
• Bron AJ, McLendon BF, Camp AV. Epithelial deposition of gold in the cornea in patients receiving systemic therapy. Am J Ophthalmol 1979;88(3 Pt 1):354-60
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Maeda Y, Ito H, Corneal chrysiasis. A clinical study in rheumatoid arthritis patients receiving gold therapy. Arthritis Rheum 1972;15(3):309-15
   PubMed Web of Science ®Google Scholar
• Paladini I, Menchini U, Mencucci R. Corneal chrysiasis: in vivo confocal microscopy analysis. Eur J Ophthalmol 2010;20(4):776-9
   PubMed Web of Science ®Google Scholar
• Lopez JD, del Castillo JM, Lopez CD, Sanchez JG. Confocal microscopy in ocular chrysiasis. Cornea 2003;22(6):573-5
   PubMed Web of Science ®Google Scholar
• Bhagat N, Read RW, Rao NA, Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. Ophthalmology 2001;108(4):750-2
   PubMed Web of Science ®Google Scholar
• Schaller UC, Michl G, Goebel FD, Klauss V. Acute hypopyon uveitis with rifabutin therapy of systemic Mycobacterium avium complex (MAC) infection in AIDS. Ophthalmologe 1999;96(4):267-9
   PubMed Web of Science ®Google Scholar
• Frau E, Gregoire-Cassoux N, Hannouche D, Uveitis with hypopyon in patients with acquired immunodeficiency syndrome, treated with Rifabutin. J Fr Ophtalmol 1995;18(6-7):435-8
   PubMed Web of Science ®Google Scholar
• Saran BR, Maguire AM, Nichols C, Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994;112(9):1159-65
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Freeman WR. Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Am J Ophthalmol 2000;129(3):410-11
   PubMed Web of Science ®Google Scholar
• Holland SP, Chang CW, Vagh M, Courtright P. Corneal endothelial deposits in patients with HIV infection or AIDS: epidemiologic evidence of the contribution of rifabutin. Can J Ophthalmol 1999;34(4):204-9
   PubMed Web of Science ®Google Scholar
• Ponjavic V, Granse L, Bengtsson Stigmar E, Andreasson S. Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin. Acta Ophthalmol Scand 2002;80(5):553-6
   PubMedGoogle Scholar
• Smith JA, Mueller BU, Nussenblatt RB, Whitcup SM. Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Am J Ophthalmol 1999;127(2):164-9
   PubMed Web of Science ®Google Scholar
• Nambiar S, Rellosa N, Wassel RT, Linezolid-associated peripheral and optic neuropathy in children. Pediatrics 2011;127(6):e1528-382
   Google Scholar
• Rucker JC, Hamilton SR, Bardenstein D, Linezolid-associated toxic optic neuropathy. Neurology 2006;66(4):595-8
   PubMed Web of Science ®Google Scholar
• Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf 2008;31(2):127-41
   PubMed Web of Science ®Google Scholar
• Lee E, Burger S, Shah J, Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003;37(10):1389-91
   PubMed Web of Science ®Google Scholar
• Le-Nguyen XT, Lee TK, Do DV, Diagnostic and therapeutic challenges. Retina 2011;31(8):1732-9
   PubMed Web of Science ®Google Scholar
• Arnold AC. Ischemic optic neuropathies. Ophthalmol Clin North Am 2001;14(1):83-98
   PubMedGoogle Scholar
• Sharma P, Sharma R. Toxic optic neuropathy. Indian J Ophthalmol 2011;59(2):137-41
   PubMed Web of Science ®Google Scholar
• Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999;127(5):610-12
   PubMed Web of Science ®Google Scholar
• Kokkada SB, Barthakur R, Natarajan M, Ocular side effects of antitubercular drugs - a focus on prevention, early detection and management. Kathmandu Univ Med J (KUMJ) 2005;3(4):438-41
   PubMedGoogle Scholar
• Vistamehr S, Walsh TJ, Adelman RA. Ethambutol neuroretinopathy. Semin Ophthalmol 2007;22(3):141-6
   PubMedGoogle Scholar
• Chai SJ, Foroozan R. Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. Br J Ophthalmol 2007;91(7):895-7
   PubMed Web of Science ®Google Scholar
• Chan RY, Kwok AK. Ocular toxicity of ethambutol. Hong Kong Med J 2006;12(1):56-60
   PubMedGoogle Scholar
• Dillberger JE, Peiffer RL, Dykstra MJ, The experimental antipsychotic agent 1192U90 targets tapetum lucidum in canine eyes. Toxicol Pathol 1996;24(5):595-601
   PubMed Web of Science ®Google Scholar
• Vogel AW, Kaiser JA. Ethambutol-induced transient change and reconstitution (in Vivo) of the tapetum lucidum color in the dog. Exp Mol Pathol 1963;26:136-49
   Google Scholar
• Kozak SF, Inderlied CB, Hsu HY, The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy. Diagn Microbiol Infect Dis 1998;30(2):83-7
   PubMed Web of Science ®Google Scholar
• Lauer AK, Wobig JL, Shults WT, Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy. Am J Ophthalmol 1999;127(2):230-3
   PubMed Web of Science ®Google Scholar
• Ponjavic V, Granse L, Kjellstrom S, Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin. Doc Ophthalmol 2004;108(2):125-33
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Sato E, Takahashi A, Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci 2007;48(1):368-75
   PubMed Web of Science ®Google Scholar
• Kadayifcilar S, Boyacioglu S, Kart H, Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye (Lond) 1999;13(Pt 2):241-6
   PubMedGoogle Scholar
• Engelke M, Tykhonova S, Zorn-Kruppa M, Diehl H. Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407. Pharmacol Toxicol 2002;91(1):13-21
   PubMedGoogle Scholar
• Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 1994;117(6):772-5
   PubMed Web of Science ®Google Scholar
• Toler SM. Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy. Exp Biol Med (Maywood) 2004;229(7):607-15
   PubMed Web of Science ®Google Scholar
• Drenser K, Sarraf D, Jain A, Small KW. Crystalline retinopathies. Surv Ophthalmol 2006;51(6):535-49
   PubMed Web of Science ®Google Scholar
• Parkkari M, Paakkala AM, Salminen L, Holli K. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand 2003;81(5):495-9
   PubMedGoogle Scholar
• Ibanez HE, Williams DF, Boniuk I. Crystalline retinopathy associated with long-term nitrofurantoin therapy. Arch Ophthalmol 1994;112(3):304-5
   PubMed Web of Science ®Google Scholar
• Kammire LD, Donofrio PD. Nitrofurantoin neuropathy: a forgotten adverse effect. Obstet Gynecol 2007;110(2 Pt 2):510-12
   PubMed Web of Science ®Google Scholar
• Loo JL, Lee SY, Ang CL. Can long-term corticosteriods lead to blindness? A case series of central serous chorioretinopathy induced by corticosteroids. Ann Acad Med Singapore 2006;35(7):496-9
   PubMed Web of Science ®Google Scholar
• Kishi S, Yoshida O, Matsuoka R, Kojima Y. Serous retinal detachment in patients under systemic corticosteroid treatment. Jpn J Ophthalmol 2001;45(6):640-7
   PubMed Web of Science ®Google Scholar
• Wegner A, Khoramnia R. Neurosensory retinal detachment due to sunitinib treatment. Eye (Lond) 2011;25(11):1517-18
   PubMed Web of Science ®Google Scholar
• Barot M, Gokulgandhi MR, Mitra AK. Mitochondrial dysfunction in retinal diseases. Curr Eye Res 2011;36(12):1069-77
   PubMed Web of Science ®Google Scholar
• Beyenburg S, Weyland C, Reuber M. Presumed topiramate-induced maculopathy. Epilepsy Behav 2009;14(3):556-9
   PubMed Web of Science ®Google Scholar
• Kjellstrom S, Bruun A, Isaksson B, Retinal function and histopathology in rabbits treated with Topiramate. Doc Ophthalmol 2006;113(3):179-86
   PubMed Web of Science ®Google Scholar
• Shinjo SK, Maia OO Jr, Tizziani VA, Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration? Clin Rheumatol 2007;26(8):1248-53
   PubMed Web of Science ®Google Scholar
• Parthasarathi S, Myint K, Singh G, Bilateral acetazolamide-induced choroidal effusion following cataract surgery. Eye (Lond) 2007;21(6):870-2
   PubMed Web of Science ®Google Scholar
• Mahesh G, Giridhar A, Saikumar SJ, Fegde S. Drug-induced acute myopia following chlorthalidone treatment. Indian J Ophthalmol 2007;55(5):386-8
   PubMedGoogle Scholar
• Schmid KE, Kornek GV, Scheithauer W, Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 2006;51(1):19-40
   PubMed Web of Science ®Google Scholar
• Hilliard LM, Berkow RL, Watterson J, Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol 1997;28(4):310-13
   PubMedGoogle Scholar
• Shingleton BJ, Bienfang DC, Albert DM, Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 1982;100(11):1766-72
   PubMed Web of Science ®Google Scholar
• Boulton M, Rozanowska M, Rozanowski B. Retinal photodamage. J Photochem Photobiol B 2001;64(2-3):144-61
   PubMed Web of Science ®Google Scholar
• Rozanowska M, Sarna T, Land EJ, Truscott TG. Free radical scavenging properties of melanin interaction of eu- and pheo-melanin models with reducing and oxidising radicals. Free Radic Biol Med 1999;26(5-6):518-25
   PubMed Web of Science ®Google Scholar
• Mecklenburg L, Schraermeyer U. An overview on the toxic morphological changes in the retinal pigment epithelium after systemic compound administration. Toxicol Pathol 2007;35(2):252-67
   PubMed Web of Science ®Google Scholar
• Leblanc B, Jezequel S, Davies T, Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol 1998;28(2):124-32
   PubMed Web of Science ®Google Scholar
• Marmor MF, Carr RE, Easterbrook M, Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109(7):1377-82
   PubMed Web of Science ®Google Scholar
• Eves P, Smith-Thomas L, Hedley S, A comparative study of the effect of pigment on drug toxicity in human choroidal melanocytes and retinal pigment epithelial cells. Pigment Cell Res 1999;12(1):22-35
   PubMedGoogle Scholar
• Larsson BS. Interaction between chemicals and melanin. Pigment Cell Res 1993;6(3):127-33
   PubMedGoogle Scholar
• Buszman E, Rozanska R. Interaction of thioridazine with ocular melanin in vitro. Acta Pol Pharm 2003;60(4):257-61
   PubMedGoogle Scholar
• To TQ, Townsend JC. Ocular toxicity of systemic medications: a case series. Optometry 2000;71(1):29-39
   PubMedGoogle Scholar
• Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 2008;27(3):197-206
   PubMed Web of Science ®Google Scholar
• Santodomingo-Rubido J, Barrado-Navascues E, Rubido-Crespo MJ. Drug-induced ocular side-effects with isotretinoin. Ophthalmic Physiol Opt 2008;28(5):497-501
   PubMed Web of Science ®Google Scholar
• Choong YY, Lim KS. Phenothiazine deposits in corneo and lens. Med J Malaysia 2001;56(1):92-4
   PubMedGoogle Scholar
• Bratulescu M, Zemba M, Gheorghieva V, Ocular manifestation in amiodarone toxicity–case report. Oftalmologia 2005;49(4):18-23
   PubMedGoogle Scholar
• Chilov MN, Moshegov CN, Booth F. Unilateral amiodarone keratopathy. Clin Experiment Ophthalmol 2005;33(6):666-8
   PubMedGoogle Scholar
• Domingues MF, Barros H, Falcao-Reis FM. Amiodarone and optic neuropathy. Acta Ophthalmol Scand 2004;82(3 Pt 1):277-82
   PubMedGoogle Scholar
• Honrubia A, Andres JM, Alcaine F, Visual disorders induced by therapeutic levels of digoxin. Arch Soc Esp Oftalmol 2000;75(1):55-6
   PubMedGoogle Scholar
• Hobley A, Lawrenson J. Ocular adverse effects to the therapeutic administration of digoxin. Ophthalmic Physiol Opt 1991;11(4):391-3
   PubMedGoogle Scholar
• Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997;56(3):188-90
   PubMed Web of Science ®Google Scholar
• Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 1990;25(5):249-51
   PubMed Web of Science ®Google Scholar
• Petrohelos MA. Chloroquine-induced ocular toxicity. Ann Ophthalmol 1974;6(6):615-18
   PubMedGoogle Scholar
• Abtahi MA, Abtahi SH, Fazel F, Topiramate and the vision: a systematic review. Clin Ophthalmol 2012;6:117-31
   PubMedGoogle Scholar
• Pai K, Rajashekaran P. Glaucoma: adverse event on use of topiramate in alcohol de-addiction. Indian J Psychiatry 2011;53(2):163-5
   PubMedGoogle Scholar
• Jabbarpoor Bonyadi MH, Soheilian R, Soheilian M. Topiramate-induced bilateral anterior uveitis associated with hypopyon formation. Ocul Immunol Inflamm 2011;19(1):86-8
   PubMed Web of Science ®Google Scholar
• Hood CT, Langston RH, Schoenfield LR, Dupps WJ Jr. Amantadine-associated corneal edema treated with descemet's stripping automated endothelial keratoplasty. Ophthalmic Surg Lasers Imaging 2010;41:1-4
   PubMedGoogle Scholar
• Esquenazi S. Bilateral reversible corneal edema associated with amantadine use. J Ocul Pharmacol Ther 2009;25(6):567-70
   PubMedGoogle Scholar
• Chang KC, Kim MK, Wee WR, Lee JH. Corneal endothelial dysfunction associated with amantadine toxicity. Cornea 2008;27(10):1182-5
   PubMedGoogle Scholar
• Hughes B, Feiz V, Flynn SB, Brodsky MC. Reversible amantadine-induced corneal edema in an adolescent. Cornea 2004;23(8):823-4
   PubMedGoogle Scholar
• Fraunfelder FW, Solomon J, Mehelas TJ. Ocular adverse effects associated with cyclooxygenase-2 inhibitors. Arch Ophthalmol 2006;124(2):277-9
   PubMedGoogle Scholar
• Goldberg D, Panigrahi D, Barazi M, A case of rofecoxib-associated stevens-johnson syndrome with corneal and conjunctival changes. Cornea 2004;23(7):736-7
   PubMedGoogle Scholar
• Ah-Song R, Sasco AJ. Tamoxifen and ocular toxicity. Cancer Detect Prev 1997;21(6):522-31
   PubMedGoogle Scholar
• Fraunfelder FW, Fraunfelder FT. Oculogyric crisis in patients taking cetirizine. Am J Ophthalmol 2004;137(2):355-7
   PubMedGoogle Scholar
• Sbeity ZH, Baydoun L, Schmidt S, Loeffler KU. Visual field changes in methotrexate therapy. Case report and review of the literature. J Med Liban 2006;54(3):164-7
   PubMedGoogle Scholar
• Balachandran C, McCluskey PJ, Champion GD, Halmagyi GM. Methotrexate-induced optic neuropathy. Clin Experiment Ophthalmol 2002;30(6):440-1
   PubMedGoogle Scholar
• Harris A, Kagemann L, Ehrlich R, The effect of sildenafil on ocular blood flow. Br J Ophthalmol 2008;92(4):469-73
   PubMed Web of Science ®Google Scholar
• Su DH, Ang PS, Tow SL. Bilateral posterior ischemic optic neuropathy associated with use of sildenafil. J Neuroophthalmol 2008;28(1):75
   PubMedGoogle Scholar
• Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006;3(1):12-27
   PubMed Web of Science ®Google Scholar
• Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: case report and review of the literature. Graefes Arch Clin Exp Ophthalmol 2010;248(2):283-7
   PubMed Web of Science ®Google Scholar
• Mumoli N, Niccoli G, Scazzeri F, Infliximab-induced retrobulbar optic neuritis. QJM 2007;100(8):531
   PubMed Web of Science ®Google Scholar
• McKague M, Jorgenson D, Buxton KA. Ocular side effects of bisphosphonates: a case report and literature review. Can Fam Physician 2010;56(10):1015-17
   PubMedGoogle Scholar
• Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009;8(2):96-110
   PubMedGoogle Scholar
• Leung S, Ashar BH, Miller RG. Bisphosphonate-associated scleritis: a case report and review. South Med J 2005;98(7):733-5
   PubMed Web of Science ®Google Scholar
• Stewart O, Chang B, Bradbury J. Simultaneous administration of hepatitis B and polio vaccines associated with bilateral optic neuritis. Br J Ophthalmol 1999;83(10):1200-1
   PubMedGoogle Scholar
• van de Geijn EJ, Tukkie R, van Philips LA, Punt H. Bilateral optic neuritis with branch retinal artery occlusion associated with vaccination. Doc Ophthalmol 1994;86(4):403-8
   PubMedGoogle Scholar
• Kulkarni HS, Keskar VS, Bavdekar SB, Gabhale Y. Bilateral optic neuritis due to isoniazid (INH). Indian Pediatr 2010;47(6):533-5
   PubMedGoogle Scholar
• Whitcup SM, Butler KM, Caruso R, Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine. Am J Ophthalmol 1992;113(1):1-7
   PubMedGoogle Scholar
• Meyer CH, Schmidt JC, Rodrigues EB, Mennel S. Risk of retinal vein occlusions in patients treated with rofecoxib (vioxx). Ophthalmologica 2005;219(4):243-7
   PubMedGoogle Scholar
• Rapp P, Pilon F, Chiambaretta F, Bilateral uveitis with definitive hypotony caused by systemic cidofovir. J Fr Ophtalmol 2003;26(7):717-19
   PubMedGoogle Scholar